Chartsonlygoup's future update (it'll live): tomwong.xyz/stock-status/

What is AMGN's Cash Flow From Operations Ratio?

  Amgen Inc ( AMGN ) |
1989 - 2021 (33 years)

Cash Flow From Operations Ratio is 
0.24 (1Y +3.1% )

AMGN Stock Price & Cash Flow From Operations Ratio

Cash Flow From Operations Ratio for AMGN competitors.
ALXN CELG GILD BIIB GSK BMY JNJ PFE ABBV
Note: Stonk = Stock. Both words are used interchangeably. 🙂

Historical (All-Time) Stats for Cash Flow From Operations Ratio

chevron_right 2021 0.18 +7.5x *
( +6.7% / year avg)
chevron_left 1989 -0.02
vertical_align_top Peak 0.56 +26.8x *
vertical_align_bottom Bottom -0.02
arrow_drop_up # Up Years 17 17 of 33
years up.
arrow_drop_down # Down Years 16
Up Years = Positive (0%+) YoY change
Down Years = Zero or Negative (0% or less) YoY change

Key Points (Stonk Price Comparison)

  • AMGN's stock price has rallied +113,400% from $0.22 in 1989 , or -119.3x faster than it's cash flow from operations ratio over the same period.
  • If AMGN grows it's stock at the same rate as it's cash flow from operations ratio (+6.7%/year) , it's stock price will grow +191% and hit $471.96 over the next 10 years.
  • AMGN's stock price has gone up 0 of the 17 years (0%) it's cash flow from operations ratio were also up.
* A modified method (see: here) is used to calculate changes that involve negative numbers.
5-Year Change 🚀
+19.8%$26.5BNet Revenue (Sales)
+49.1%$6.4BCost of Revenue (Sales)
+12.8%$20.1BGross Profit Margin
-5.86%3.04Gross Profit Margin Ratio
+12.4%$4.9BResearch and Development (R&D)
+25.2%$7.1BSelling, General, and Administrative (SG&A)
+24.5%$12.1BTotal Operating Expenses
+32.1%$18.5BCost & Expenses
+12.0%$1.3BInterest Expense/Income, Net
+61.1%$3.5BDepreciation & Amortization (D&A)
+11.9%$11.5BEBITDA
-6.63%1.74EBITDA Margin
-1.23%$8.0BOperating Income
-17.6%1.21Operating Margin
-1.88%$7.5BPretax Income (Earnings)
-18.1%1.13Pretax Income (Earnings) Margin
+131%$1.0BProvision For Income Taxes
-10.3%$6.5BNet Income (Earnings)
-25.1%0.97Net Profit Margin
+15.5%11.04Earnings Per Share (EPS)
+16.5%11.04Earnings Per Share (EPS) Diluted
-22.4%$2.3BShares Outstanding
-23.1%$2.3BShares Outstanding (Diluted)
+51.2%$25.1BCash and Cash Equivalents
-83.9%$17.5BShort Term Investments
-66.1%$42.6BCash And Short-Term Investments
+59.9%$15.6BInventory
+21.9%$8.3BOther Current Assets
-45.1%$84.6BTotal Current Assets
+42.5%$66.3BIntangible Assets
+18.3%$125.1BGoodwill and Intangible Assets
-12.1%$251.8BTotal Assets
+47.3%$5.7BAccounts Payables
-96.0%$364.0MShort-term Debt
+34.5%$46.6BTotal Current Liabilities
+12.2%$131.6BLong-term Debt
-38.3%$8.1BOther Non-Current Liabilities
+20.3%$167.5BTotal Non-Current Liabilities
+23.1%$214.2BTotal Liabilities
+3.76%$127.2BCommon Stock
+926%-$85.6BRetained Earnings
+105%-$3.9BAccumulated Other Comprehensive Income Loss
-66.5%$37.6BTotal Shareholders Equity
-12.1%$251.8BTotal Liabilities & Stockholders Equity
+4.53%$131.9BTotal Debt
-2.52%$106.9BNet Debt
-114.6%$208.0MDeferred Income Tax
+312%$1.3BStock-Based Compensation (SBC)
+76.0%-$12.9BChange in Working Capital
+235%-$1.6BAccounts Receivables
-68.2%$38.0BOther Working Capital
+161%-$1.9BOther Non-Cash Items
+4.51%$8.6BNet Cash Provided by Operating Activities
-15.6%-$692.0MInvestments in PP&E
-49.1%-$12.6BPurchase of Investments
-69.0%$8.2BSales/Maturities of Investments
-48.8%-$164.0MOther Investing Activities
+493%-$5.5BNet Cash used for Investing Activities
+1,060%-$5.8BDebt Repayment
+558%-$4.8BCommon Stock Repurchased
+56.4%-$3.7BDividends Paid
-87.0%-$12.0MOther Financing Activities
+294%-$14.4BNet Cash Used Provided by Financing Activities
-407.3%-$11.3BNet Change in Cash
+51.2%$25.1BCash at End of Period
+181%$36.3BCash at Beginning of Period
+4.51%$8.6BOperating Cash Flow
-15.6%-$692.0MCapital Expenditure (capex)
+6.74%$7.9BFree Cash Flow
  • AMGN Historical Cash Flow From Operations Ratio Table

    * A modified method (see: here) is used to calculate changes that involve negative numbers.
    Year Cash Flow From Operations Ratio YoY % Change* Stock Price YoY % Change (Stock Price)
    4/1/2021 0.18 -25.0% - -
    4/1/2020 0.25 18.7% - -
    4/1/2019 0.21 -20.6% - -
    4/1/2018 0.26 -14.5% - -
    4/1/2017 0.31 27.1% - -
    4/1/2016 0.24 -29.7% - -
    4/1/2015 0.34 40.5% - -
    4/1/2014 0.24 -3.7% - -
    4/1/2013 0.25 13.0% - -
    4/1/2012 0.22 -16.1% - -
    4/1/2011 0.27 -1.2% - -
    4/1/2010 0.27 -13.1% - -
    4/1/2009 0.31 13.7% - -
    4/1/2008 0.27 1.6% - -
    4/1/2007 0.27 5.5% - -
    4/1/2006 0.25 -1.2% - -
    4/1/2005 0.26 -1.4% - -
    4/1/2004 0.26 -47.8% - -
    4/1/2003 0.5 16.8% - -
    4/1/2002 0.43 1.5% - -
    4/1/2001 0.42 -24.2% - -
    4/1/2000 0.56 75.4% - -
    4/1/1999 0.32 5.0% - -
    4/1/1998 0.3 -23.0% - -
    4/1/1997 0.39 16.0% - -
    4/1/1996 0.34 4.2% - -
    4/1/1995 0.33 8.0% - -
    4/1/1994 0.3 -25.8% - -
    4/1/1993 0.41 95.7% - -
    4/1/1992 0.21 -31.4% - -
    4/1/1991 0.3 197.0% - -
    4/1/1990 0.1 -570.0% - -
    4/1/1989 -0.02 - - -

  • About
    Industry: Drug Manufacturers General
    Sector: Healthcare
    Country: US
    IPO Date: 5/1/1987
    Stonk Exchange: NASDAQ
    • Amgen, Inc
    • is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics.
    • The company is headquartered in Thousand Oaks, California and currently employs 21,500 full-time employees.
    • The firm discovers, develops, manufactures and delivers various human therapeutics.
    • The company operates in human therapeutics segment.
    • Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
    • The company focuses on human therapeutics for the treatment of serious illness in the areas of oncology/hematology, cardiovascular disease and neuroscience.
    • Its product candidates in Phase III include Erenumab for episodic migraine, Aranesp for myelodysplastic syndromes, BLINCYTO for acute lymphoblastic leukemia and IMLYGIC for metastatic melanoma.
  • Cash flow from operations ratio = Cash Flow from Operations / Current Liability


    For more detailed definitions, please see Investopedia.
    Year Cash Flow From Operations Ratio YoY % Change Stock Price YoY % Change (Stock Price) total current liabilities operating cash flow
    4/1/2021 0.18 -25.0% 46612.00 8612.00
    4/1/2020 0.25 18.7% 45138.00 10858.00
    4/1/2019 0.21 -20.6% 47553.00 9830.00
    4/1/2018 0.26 -14.5% 43136.00 11114.00
    4/1/2017 0.31 27.1% 37735.00 11265.00
    4/1/2016 0.24 -29.7% 38562.00 9314.00
    4/1/2015 0.34 40.5% 27400.00 9462.00
    4/1/2014 0.24 -3.7% 32567.00 7945.00
    4/1/2013 0.25 13.0% 22960.00 5268.00
    4/1/2012 0.22 -16.1% 30451.00 6654.00
    4/1/2011 0.27 -1.2% 20716.00 5543.00
    4/1/2010 0.27 -13.1% 22687.00 5602.00
    4/1/2009 0.31 13.7% 19010.00 5910.00
    4/1/2008 0.27 1.6% 22513.00 6121.00
    4/1/2007 0.27 5.5% 20086.00 5113.00
    4/1/2006 0.25 -1.2% 21179.00 5276.00
    4/1/2005 0.26 -1.4% 18968.00 4892.00
    4/1/2004 0.26 -47.8% 17207.80 3784.50
    4/1/2003 0.50 16.8% 6349.60 3189.20
    4/1/2002 0.43 1.5% 4744.30 1954.20
    4/1/2001 0.42 -24.2% 3139.60 1326.40
    4/1/2000 0.56 75.4% 3052.93 1683.87
    4/1/1999 0.32 5.0% 3415.60 1084.24
    4/1/1998 0.30 -23.0% 3309.10 998.80
    4/1/1997 0.39 16.0% 2403.90 942.40
    4/1/1996 0.34 4.2% 2240.20 770.80
    4/1/1995 0.33 8.0% 2248.60 732.30
    4/1/1994 0.30 -25.8% 1533.20 462.20
    4/1/1993 0.41 95.7% 1234.00 501.40
    4/1/1992 0.21 -31.4% 1372.00 284.80
    4/1/1991 0.30 197.0% 1059.60 320.40
    4/1/1990 0.10 -570.0% 297.80 48.80
    4/1/1989 -0.02 71.33 -7.80